Global Gastric Cancer Drug Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Запрос на TOC Запрос на TOC Обратиться к аналитику Обратиться к аналитику Купить сейчас Купить сейчас Узнать перед покупкой Узнать перед покупкой Бесплатный пример отчета Бесплатный пример отчета

Global Gastric Cancer Drug Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

  • Healthcare
  • Upcoming Report
  • Jan 2025
  • Global
  • 350 Pages
  • Количество таблиц: 60
  • Количество рисунков: 220

Global Gastric Cancer Drug Market

Размер рынка в млрд долларов США

CAGR :  % Diagram

Chart Image USD 5.28 Billion USD 16.11 Billion 2024 2032
Diagram Прогнозируемый период
2025 –2032
Diagram Размер рынка (базовый год)
USD 5.28 Billion
Diagram Размер рынка (прогнозируемый год)
USD 16.11 Billion
Diagram CAGR
%
Diagram Основные игроки рынка
  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5

>Global Gastric Cancer Drug Market Segmentation, By Type (Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor, and Others), Treatment Type (Chemotherapy, Targeted Therapy, Immunotherapy, Surgery, Radiation therapy, Medication, and Others), Drug Type (Doxorubicin Hydrochloride, Sunitinib Mitomycin, Imatinib, Fluorouracil, Trastuzumab, and Others), Route of Administration (Oral and injectable), End- Users (Hospitals, Homecare, Specialty Clinics, and Others) – Industry Trends and Forecast to 2032

Gastric Cancer Drug Market

Gastric Cancer Drug Market Analysis

The gastric cancer drug market is witnessing significant growth, driven by advancements in oncology research and an increasing global burden of stomach cancer. According to the World Health Organization (WHO), gastric cancer remains one of the leading causes of cancer-related deaths worldwide, with over a million new cases reported annually. The growing awareness of early diagnosis and the adoption of advanced treatment modalities have further propelled market expansion. Technological innovations, such as the development of targeted therapies, immunotherapies, and companion diagnostics, are transforming the treatment landscape. For instance, therapies such as trastuzumab deruxtecan have shown remarkable efficacy in treating HER2-positive gastric cancer, offering new hope for patients with limited options. In addition, advancements in biomarker identification are enabling personalized medicine approaches, ensuring more effective and tailored treatments. Geographically, North America dominates the market due to its robust healthcare infrastructure and extensive R&D activities, while the Asia-Pacific region is expected to witness the highest growth due to the rising prevalence of gastric cancer and improving healthcare systems. Overall, the market's trajectory is shaped by a combination of innovation, rising disease prevalence, and increasing investments in cancer research.

Gastric Cancer Drug Market Size

The global gastric cancer drug market size was valued at USD 5.28 billion in 2024 and is projected to reach USD 16.11 billion by 2032, with a CAGR of 14.95% during the forecast period of 2025 to 2032. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Gastric Cancer Drug Market Trends

Rise of Targeted Therapies and Immunotherapies”

A key trend shaping the gastric cancer drug market is the rise of targeted therapies and immunotherapies, driven by advancements in molecular biology and precision medicine. These treatments are designed to target specific genetic markers or proteins associated with gastric cancer, improving efficacy and reducing side effects compared to traditional therapies. For instance, the approval of trastuzumab deruxtecan for HER2-positive gastric cancer patients has opened new avenues for treating cases with limited therapeutic options. In addition, checkpoint inhibitors such as pembrolizumab are being explored for their potential in treating advanced or metastatic gastric cancers. This trend aligns with the increasing emphasis on personalized medicine, which tailors treatments based on individual patient profiles. The growing pipeline of such therapies and the integration of companion diagnostics to identify suitable candidates further highlight the shift towards innovative and patient-centric solutions, significantly influencing the market's growth trajectory.

Report Scope and Gastric Cancer Drug Market Segmentation

Attributes

Gastric Cancer Drug Key Market Insights

Segments Covered

  • By Type: Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor, and Others
  • By Treatment Type: Chemotherapy, Targeted Therapy, Immunotherapy, Surgery, Radiation therapy, Medication, and Others
  • By Drug Type: Doxorubicin Hydrochloride, Sunitinib Mitomycin, Imatinib, Fluorouracil, Trastuzumab, and Others
  • By Route of Administration: Oral and injectable
  • By End- Users: Hospitals, Homecare, Specialty Clinics, and Others

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Key Market Players

Imugene Limited (Australia), Otsuka Pharmaceuticals Co., Ltd (Japan), Immutep (Australia), F. Hoffmann-La Roche Ltd (Switzerland), Merck KGaA (Germany), Bristol-Myers Squibb Company (U.S.), Novartis AG (Switzerland), Lilly (U.S.), Sanofi (France), Amgen Inc. (U.S.), Bayer AG (Germany), Gilead Sciences, Inc. (U.S.), AstraZeneca (U.K.), Ipsen Pharma (France), Takeda Pharmaceutical Company Limited (Japan), Biosplice Therapeutics, Inc. (U.S.), Arbutus Biopharma (Canada), ASLAN Pharmaceuticals (Singapore)

Market Opportunities

  • Increasing Advancements in Targeted Therapies and Immunotherapies
  • Growing Awareness and Early Diagnosis

Value Added Data Infosets

In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Gastric Cancer Drug Market Definition

Gastric cancer drugs refer to a range of therapeutic agents specifically designed to treat gastric (stomach) cancer, a malignant condition originating in the lining of the stomach. These drugs encompass various treatment approaches, including chemotherapy, targeted therapy, immunotherapy, and supportive medications aimed at managing symptoms or improving quality of life.

Gastric Cancer Drug Market Dynamics

Drivers

  • Increasing Aging Population

The aging population is a significant driver of the gastric cancer drug market. According to the United Nations, the global population aged 60 years and above is expected to reach 2.1 billion by 2050, contributing to an increased risk of gastric cancer, particularly in older adults. Studies show that the incidence of gastric cancer rises with age, with the highest rates observed in individuals over 70. As this demographic grows, there is an increasing demand for effective, age-appropriate therapies that can address both the unique medical needs and comorbidities of elderly patients. This includes drugs with fewer side effects, tailored treatment regimens, and improved efficacy for older populations who may have compromised health. For instance, trastuzumab deruxtecan, a targeted therapy for HER2-positive gastric cancer, has shown promising results in older patients with advanced cancer, highlighting the need for treatments that cater to this age group. This trend is shaping the market, as pharmaceutical companies focus on developing and delivering therapies suited to an aging global population.

  • Rising Incidence of Gastric Cancer

The rising incidence of gastric cancer is a key driver of the gastric cancer drug market. According to the World Health Organization (WHO), gastric cancer remains one of the leading causes of cancer-related deaths globally, with over 1 million new cases reported annually. This growing incidence, particularly in regions such as East Asia, where the disease is more prevalent, is fueling demand for advanced treatment options. For instance, countries such as Japan and South Korea report some of the highest gastric cancer rates, necessitating innovative therapies and early intervention strategies. The increasing number of diagnosed cases creates a greater need for effective drugs, such as chemotherapies and targeted therapies, that can help manage the disease. In addition, advancements in precision medicine are pushing the development of drugs that target specific genetic mutations, offering patients more personalized and effective treatment plans. As the global burden of gastric cancer continues to rise, pharmaceutical companies are prioritizing the development of new therapies to meet this escalating need, driving market growth.

Opportunities

  • Increasing Advancements in Targeted Therapies and Immunotherapies

Advancements in targeted therapies and immunotherapies represent a significant market opportunity in the gastric cancer drug market. Innovations such as HER2-targeting drugs such as trastuzumab and checkpoint inhibitors such as pembrolizumab are revolutionizing gastric cancer treatment by offering more personalized and effective options for patients. Trastuzumab targets the HER2 receptor, found in some gastric cancers, and has shown improved survival rates in HER2-positive patients. Similarly, pembrolizumab, an immune checkpoint inhibitor, has demonstrated promise in treating advanced gastric cancer by enhancing the body's immune response against tumor cells. These therapies are particularly valuable for patients with advanced or metastatic gastric cancer, where traditional treatments often fail. The growing success of these therapies is driving increased investment in biomarker-based diagnostics and personalized treatment regimens. With the ongoing approval of new immunotherapies and targeted drugs, such as trastuzumab deruxtecan, this trend presents a significant opportunity for pharmaceutical companies to expand their portfolios and meet the rising demand for advanced gastric cancer treatments.

  • Growing Awareness and Early Diagnosis

Growing awareness and early diagnosis are becoming significant market opportunities in the gastric cancer drug market. With improved awareness campaigns globally, patients are increasingly recognizing the early signs of gastric cancer, leading to earlier detection. In regions such as Japan, where gastric cancer rates are high, public health campaigns focus on educating the population about risk factors such as Helicobacter pylori infection and dietary habits, which can help in detecting cancer at earlier, more treatable stages. Advancements in diagnostic technologies such as endoscopy and biomarker testing are enhancing the accuracy of early diagnosis, enabling healthcare providers to identify gastric cancer before it progresses to advanced stages. This trend is driving the demand for therapeutic interventions, as early-stage patients are more likely to respond well to treatment, creating a broader market for drugs such as targeted therapies and chemotherapy. Furthermore, innovations such as liquid biopsies are making diagnostic tools more accessible, opening new market opportunities for pharmaceutical companies to offer effective treatment options for early-stage gastric cancer patients.

Restraints/Challenges

  • Regulatory Hurdles

Regulatory hurdles in the approval process for novel gastric cancer treatments, such as immunotherapies and gene-targeted therapies, can significantly delay the introduction of new drugs to the market and increase development costs. The process typically involves multiple phases of clinical trials, stringent safety evaluations, and the submission of detailed data, all of which can take years to complete. For instance, the approval of pembrolizumab (Keytruda) for gastric cancer by the U.S. FDA took several years of trials and regulatory reviews, adding considerable costs and time to its market entry. These lengthy and complex regulatory procedures can discourage pharmaceutical companies from pursuing innovative treatments, particularly for less common cancers such as gastric cancer, where the market potential may appear smaller. As a market challenge, these delays limit the availability of cutting-edge therapies and inflate drug prices, reducing their accessibility and increasing the financial burden on healthcare systems, especially in regions with limited resources.

  • High Treatment Costs

High treatment costs for gastric cancer drugs, particularly targeted therapies and immunotherapies, present a significant barrier to accessibility, especially in lower-income regions. The development of these advanced treatments often involves complex, resource-intensive research and clinical trials, driving up their cost. For instance, immunotherapy drugs such as pembrolizumab (Keytruda) or nivolumab (Opdivo), which are used to treat advanced gastric cancer, are priced at thousands of dollars per treatment cycle. In countries with limited healthcare budgets, such as in many parts of Southeast Asia or Latin America, the high costs can make these therapies prohibitively expensive, resulting in limited access for patients who need them most. This economic barrier restricts the reach of potentially life-saving treatments and creates a disparity in outcomes between wealthier and less affluent populations, further complicating the global market for gastric cancer drugs. As a market challenge, it underscores the need for cost-effective solutions, such as generic options or public-private partnerships to improve accessibility and affordability.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Gastric Cancer Drug Market Scope

The market is segmented on the basis of type, treatment type, drug type, route of administration, and end-users. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

  • Adenocarcinoma
  • Lymphoma
  • Gastrointestinal Stromal Tumor
  • Carcinoid Tumor
  • Others

Treatment Type

  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy
  • Surgery
  • Radiation Therapy
  • Medication
  • Others

Drug Type

  • Doxorubicin Hydrochloride
  • Sunitinib
  • Mitomycin
  • Imatinib
  • Fluorouracil
  • Trastuzumab
  • Others

Route of Administration

  • Oral
  • Injectable

End-Users

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

Gastric Cancer Drug Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, type, treatment type, drug type, route of administration, and end-users as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the gastric cancer drug market, driven by the increasing prevalence of stomach cancer and the region's robust healthcare infrastructure. Advanced technologies in cancer research and state-of-the-art treatment centers contribute significantly to this dominance. The presence of major pharmaceutical companies and extensive funding for oncology research further bolster the region's market growth. In addition, the availability of innovative therapies and a well-established system for clinical trials ensure that North America remains at the forefront of advancements in gastric cancer treatment.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.  

Gastric Cancer Drug Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Gastric Cancer Drug Market Leaders Operating in the Market Are:

  • Imugene Limited (Australia)
  • Otsuka Pharmaceuticals Co., Ltd (Japan)
  • Immutep (Australia)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Merck KGaA (Germany)
  • Bristol-Myers Squibb Company (U.S.)
  • Novartis AG (Switzerland)
  • Lilly (U.S.)
  • Sanofi (France)
  • Amgen Inc. (U.S.)
  • Bayer AG (Germany)
  • Gilead Sciences, Inc. (U.S.)
  • AstraZeneca (U.K.)
  • Ipsen Pharma (France)
  • Takeda Pharmaceutical Company Limited (Japan)
  • Biosplice Therapeutics, Inc. (U.S.)
  • Arbutus Biopharma (Canada)
  • ASLAN Pharmaceuticals (Singapore)

Latest Developments in Gastric Cancer Drug Market

  • In October 2024, Roche received FDA approval for the VENTANA CLDN18 (43-14A) RxDx Assay, the first companion diagnostic designed to identify gastric and GEJ cancer patients eligible for Astellas’ VYLOY therapy
  • In June 2024, I-Mab, a global biotech company focused on developing differentiated immunotherapies for cancer, announced a clinical trial collaboration and supply agreement with Bristol Myers Squibb
  • In May 2024, Merck reported that the Phase 3 KEYNOTE-811 trial achieved its dual primary endpoint of overall survival for KEYTRUDA combined with trastuzumab and chemotherapy in patients with HER2-positive gastric or GEJ adenocarcinoma
  • In April 2024, AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) was approved in the U.S. for treating adult patients with unresectable or metastatic HER2-positive solid tumors, including breast, lung, and gastric cancers, who have received prior systemic treatment and lack satisfactory alternatives
  • In April 2024, Ono Pharmaceuticals announced the acquisition of Deciphera Pharmaceuticals in a USD 2.4 billion buyout, granting Ono access to Deciphera’s oncology candidates, including the CSF-1 inhibitor vimseltinib and the ULK kinase inhibitor DCC-3116

SKU-

Get online access to the report on the World's First Market Intelligence Cloud

  • Интерактивная панель анализа данных
  • Панель анализа компании для возможностей с высоким потенциалом роста
  • Доступ аналитика-исследователя для настройки и запросов
  • Анализ конкурентов с помощью интерактивной панели
  • Последние новости, обновления и анализ тенденций
  • Используйте возможности сравнительного анализа для комплексного отслеживания конкурентов
Запросить демонстрацию

Методология исследования

Сбор данных и анализ базового года выполняются с использованием модулей сбора данных с большими размерами выборки. Этап включает получение рыночной информации или связанных данных из различных источников и стратегий. Он включает изучение и планирование всех данных, полученных из прошлого заранее. Он также охватывает изучение несоответствий информации, наблюдаемых в различных источниках информации. Рыночные данные анализируются и оцениваются с использованием статистических и последовательных моделей рынка. Кроме того, анализ доли рынка и анализ ключевых тенденций являются основными факторами успеха в отчете о рынке. Чтобы узнать больше, пожалуйста, запросите звонок аналитика или оставьте свой запрос.

Ключевой методологией исследования, используемой исследовательской группой DBMR, является триангуляция данных, которая включает в себя интеллектуальный анализ данных, анализ влияния переменных данных на рынок и первичную (отраслевую экспертную) проверку. Модели данных включают сетку позиционирования поставщиков, анализ временной линии рынка, обзор рынка и руководство, сетку позиционирования компании, патентный анализ, анализ цен, анализ доли рынка компании, стандарты измерения, глобальный и региональный анализ и анализ доли поставщика. Чтобы узнать больше о методологии исследования, отправьте запрос, чтобы поговорить с нашими отраслевыми экспертами.

Доступна настройка

Data Bridge Market Research является лидером в области передовых формативных исследований. Мы гордимся тем, что предоставляем нашим существующим и новым клиентам данные и анализ, которые соответствуют и подходят их целям. Отчет можно настроить, включив в него анализ ценовых тенденций целевых брендов, понимание рынка для дополнительных стран (запросите список стран), данные о результатах клинических испытаний, обзор литературы, обновленный анализ рынка и продуктовой базы. Анализ рынка целевых конкурентов можно проанализировать от анализа на основе технологий до стратегий портфеля рынка. Мы можем добавить столько конкурентов, о которых вам нужны данные в нужном вам формате и стиле данных. Наша команда аналитиков также может предоставить вам данные в сырых файлах Excel, сводных таблицах (книга фактов) или помочь вам в создании презентаций из наборов данных, доступных в отчете.

Часто задаваемые вопросы

Рынок сегментирован на основе Segmentation, By Type (Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor, and Others), Treatment Type (Chemotherapy, Targeted Therapy, Immunotherapy, Surgery, Radiation therapy, Medication, and Others), Drug Type (Doxorubicin Hydrochloride, Sunitinib Mitomycin, Imatinib, Fluorouracil, Trastuzumab, and Others), Route of Administration (Oral and injectable), End- Users (Hospitals, Homecare, Specialty Clinics, and Others) – Industry Trends and Forecast to 2032 .
Размер Global Gastric Cancer Drug Market в 2024 году оценивался в 5.28 USD Billion долларов США.
Ожидается, что Global Gastric Cancer Drug Market будет расти со среднегодовым темпом роста (CAGR) 14.95% в течение прогнозируемого периода 2025–2032.
Отчет по рынку охватывает данные из U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Testimonial